Cancer drug study halted early: what we know

NCT ID NCT05821777

Terminated Disease control Sponsor: Centessa Pharmaceuticals (UK) Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called LB101 in 25 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check safety and see if the drug shrank tumors. The study was terminated early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer colorectal cancer gastric cancer head and neck squamous cell carcinoma non-small cell lung carcinoma ovarian cancer skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Locations

Institut Gustave Roussy

Villejuif, 94805, France
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
NEXT Oncology

San Antonio, Texas, 78229, United States
NEXT Oncology - Dallas

Irving, Texas, 75039, United States
Sarah Cannon Research Institute at Florida Cancer Specialists

Sarasota, Florida, 34232, United States
Sarah Cannon Research Institute at HealthONE.

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute at Tennessee Oncology Nashville

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.